| Date Filed | Type | Description |
| 08/21/2023 |
8-K
| Other Events Interactive Data |
| 08/16/2023 |
3
| German Christopher Paul (Corporate Controller & CAO) has filed a Form 3 on RHYTHM PHARMACEUTICALS, INC. |
| 08/09/2023 |
4
| Lee Jennifer Kayden (EVP, Head of North America) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Sold 11,223 shares
@ $24.1778, valued at
$271.3k
Sold 1,718 shares
@ $24.66, valued at
$42.4k
Exercised 8,591 options to buy
@ $6.8, valued at
$58.4k
Exercised 1,718 options to buy
@ $6.8, valued at
$11.7k
|
|
| 08/09/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/01/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 11% stake in RHYTHM PHARMACEUTICALS INC |
| 05/02/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Three months ended March 31, 2023 2022 Revenues: Product revenue, net $ 11,469 $ 1,498 Costs and expenses: Cost of sales 1,421 230 Research and development 37,945 32,510 Selling, general, and administrative 24,634 21,449 Total costs and expenses 64,000 54,189 Loss from operations Other income: Other expense, net Interest expense — Interest income 3,440 160 Total other income , net 352 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 56,708,975 50,326,627 Other comprehensive loss: Net loss $ $ Foreign currency translation adjustment 21 — Unrealized gain , net on marketable securities 65 Comprehensive loss $ $ Condensed Consolidated Balance Sheets" |
|
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/31/2023 |
4
| Roberts William T. (Chief Accounting Officer) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Sold 912 shares
@ $17.5, valued at
$16k
Exercised 2,500 restricted stock units
@ $0 |
|
| 03/06/2023 |
4
| Mathers Edward T (Director) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Acquired 5,771 shares
@ $0 |
|
| 03/02/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 03/02/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/01/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
4
| Shulman Joseph (Chief Technical Officer) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Sold 554 shares
@ $26.87, valued at
$14.9k
Exercised 1,563 restricted stock units
@ $0 |
|
| 02/14/2023 |
4
| Chien Jennifer (EVP, Head of North America) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Sold 635 shares
@ $26.87, valued at
$17.1k
Exercised 2,031 restricted stock units
@ $0 |
|
| 02/14/2023 |
4
| Smith Hunter C (CFO) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Sold 702 shares
@ $26.87, valued at
$18.9k
Exercised 2,344 restricted stock units
@ $0 |
|
| 02/14/2023 |
4
| Mazabraud Yann (EVP, Head of International) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Exercised 2,031 restricted stock units
@ $0 |
|
| 02/14/2023 |
4/A
| Cramer Pamela J. (Chief Human Resources Officer) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Sold 843 shares
@ $27.51, valued at
$23.2k
|
|
| 02/14/2023 |
4/A
| Mazabraud Yann (EVP, Head of International) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Sold 1,563 shares
@ $27.51, valued at
$43k
|
|
| 02/14/2023 |
4/A
| Roberts William T. (Chief Accounting Officer) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Sold 969 shares
@ $27.51, valued at
$26.7k
|
|
| 02/14/2023 |
4/A
| Shulman Joseph (Chief Technical Officer) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Sold 931 shares
@ $27.51, valued at
$25.6k
|
|
| 02/14/2023 |
4/A
| Chien Jennifer (EVP, Head of North America) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Sold 1,204 shares
@ $27.51, valued at
$33.1k
|
|
| 02/14/2023 |
4/A
| Smith Hunter C (CFO) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Sold 1,413 shares
@ $27.51, valued at
$38.9k
|
|
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.8% stake in RHYTHM PHARMACEUTICALS, INC. |
|